Navigation Links
An Evaluation of Clinical Trial Quality in Russia and Ukraine, new webinar hosted by Xtalks
Date:3/8/2013

Toronto, Canada (PRWEB) March 08, 2013

With patient recruitment rates up to twenty times faster than the West, the biopharmaceutical industry is embracing the undeniable benefits of conducting clinical trials in emerging markets such as Russia. In fact, 33% of all drugs approved by the FDA and 48% of all drugs approved by the EMEA in 2011 included data from clinical trial research conducted in this region.

Yet with benefits like this, why isn’t this number closer to 100%? For many, the enticement for conducting clinical trials in emerging markets is over shadowed by the fear of unknown regulatory and logistics requirements, prolonged study start-up times and overall clinical trial quality.

During the webinar, ClinStar CEO David Passov and QA Director Dr. Stanislav Gneushev will evaluate the quality of clinical trials being conducted in Russia / Ukraine compared to Western Europe, Eastern Europe and other Emerging Markets based on the results of recent FDA inspections conducted at clinical trial sites in these regions. In addition, they will:

  •     Discuss key elements of successful Quality Management Systems for niche CROs operating in Russia, Ukraine, Belarus and the Baltics
  •     Provide practical advice on SOP development
  •     Present training approaches for optimal coaching of clinical monitors
  •     Consider what quality assurance activities are required in Russia and parts of Eastern Europe to ensure continuous quality improvement of clinical studies

For more information about this event or to register, visit: http://xtks.in/xto580-event

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/3/prweb10499405.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PhaseRx Announces Technology Evaluation Agreement with Monsanto
2. Evaluation of a Single 1.000 mg Iron Dose as Ferric Carboxymaltose (FCM) for Fatigue Treatment in Iron Deficient Women - PREFER
3. New Data Shows GeNO LLC Nitric Oxide Delivery System Provided Nitric Oxide With Low Levels of Nitrogen Dioxide for Heart Transplant Patient Evaluation
4. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
5. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
6. Macrogen Corp. Announces the Inception of Macrogen Clinical Laboratory (MCL)
7. PhUSE Announces Open Source Repository of Clinical Trial Informatics Analysis Code
8. QIAGEN Unveils Sample-to-Result Next-Generation Sequencing Workflow Designed for Clinical Research and Diagnostics
9. NeoClinical Launches Neo PayPerPatient Clinical Trial Recruitment
10. Eastern Clinical Trials Russia CRO Passes EMA Inspection
11. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 On ... trading session at 5,817.69, down 0.07%; the Dow Jones ... and the S&P 500 closed at 2,345.96, marginally dropping ... sectors closed in green, 4 sectors finished in red, ... Friday, Stock-Callers.com has initiated reports coverage on the following ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... material that exhibits both viscous and elastic characteristics when deformed, which is identical ... exhibits properties to gently absorb compressive forces and return to its natural state ...
(Date:3/23/2017)... 23, 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW ... therapies for solid tumor cancers, today announced that ... it announced last Friday, March 17, 2017. ... investors securities totaling 28,843,692 shares, comprised of 18,843,692 ... shares of Class C Warrants pre-funded at the ...
(Date:3/23/2017)...  BioPharmX Corporation (NYSE MKT: BPMX), a specialty ... today reported financial results for the quarter and ... an update on the company,s clinical development efforts ... are pleased to report that last year was ... Anja Krammer. "We achieved key clinical milestones and ...
Breaking Biology Technology:
(Date:3/7/2017)... England , March 7, 2017 Brandwatch , ... chosen by The Prince,s Trust to uncover insights to ... across The Trust. The UK,s leading youth charity will ... social campaign results and get a better understanding of the topics ... ...
(Date:3/2/2017)... 2017 Summary This report provides ... KGaA and its partnering interests and activities since 2010. ... Description The Partnering Deals and Alliance since 2010 report ... one of the world,s leading life sciences companies. ... to ensure inclusion of the most up to date ...
(Date:2/28/2017)... --  Acuant , a leading provider of data capture ... new and core technologies building upon the acquisition of ... desktop Acuant FRM TM facial recognition and match ... manual review of identity documents by accredited professionals. ... most accurate capture software to streamline workflows by securely ...
Breaking Biology News(10 mins):